AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas

AbbVie reported $61.1 billion in 2025 sales with its immunology franchise driving nearly half of revenue—Skyrizi $17.5 billion, Rinvoq $8.3 billion and Humira $4.5 billion—while the immunology portfolio grew 18.3%. Management emphasized underappreciated growth opportunities in oncology and neuroscience, highlighting Parkinson’s drug Vyalev which rose 33% in Q4 to $183 million ( $482 million for the year), and signaled continued M&A interest in obesity assets (e.g., ABBV295 from Gubra) as part of portfolio diversification. Executives also defended Skyrizi/Rinvoq’s dominant position versus new competition such as J&J’s Tremfya, indicating confidence in sustained commercial momentum.

Analysis

Contrarian angles: Consensus underestimates oncology/neuroscience upside (Vyalev growth +33% Q4 and $482m FY indicates early non‑immunology revenue runway) and M&A optionality in obesity — a successful ABBV295 Phase I would re‑rate the stock. Conversely, market may be underpricing payer pushback and competition risk: if combined Skyrizi+Rinvoq sales fall >10% YoY or Tremfya gains >5–10ppt share in I&I over 12–24 months, reassess longs. Historically, incumbents with >40% franchise concentration have volatile re-ratings when payer dynamics shift; set hard stop losses and rebalancing triggers.

Key Decisions for Investors

• Establish a 2–4% long position in ABBV over the next 2 weeks; pair with 9–12 month protective puts ~5–10% OTM (size puts to cover 50–75% of equity position) to limit a downside shock from regulatory/payer news.
• Implement a relative-value pair trade: long ABBV and short JNJ equal notional exposure of 0.5–1% of portfolio for 6–18 months to capture ABBV’s better near-term revenue momentum; close or rebalance if spread in YTD total return narrows/widens by 5% absolute.
• Buy a 6–9 month ABBV call spread (buy nearer‑ATM, sell 15–20% OTM) sized to 1% notional to speculate on a positive ABBV295 Phase I readout later this year; cap premium with the sold leg.
• If ABBV shares rally >25% or combined Skyrizi+Rinvoq growth falls below +5% YoY on reported quarters, trim ABBV exposure by 50% and redeploy to diversified large-cap healthcare or buy JNJ on material pullbacks.
• Monitor the next 30–90 days for: (a) any FDA/EMA safety advisories on JAK/IL‑23 classes, (b) payer formulary decisions and rebate notices for Skyrizi/Rinvoq, and (c) ABBV295 Phase I readout timing — reduce ABBV exposure by 50% within 48 hours of adverse regulatory/payer headlines.